Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Locally Advanced/Metastatic Solid Tumors

In brief

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.

Key facts

Study ID

NCT06414460

Run by

InSilico Medicine Hong Kong Limited

People needed

114

Starts

2025-04-25

Expected to finish

2029-03-31

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female participants with age ≥18 years at the time of signing the informed consent.
• Histologically confirmed unresectable locally advanced or metastatic solid tumors with confirmed homozygous MTAP deletion, who have disease progression after standard therapy, intolerable to standard therapy, or for whom no standard therapy exists.
• Have measurable or evaluable lesions in Part 1 and at least one measurable target lesion in Part 2 as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
• ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤1.
• Life expectancy of ≥12 weeks as judged by the investigator.
• Adequate organ function as determined by medical assessment.
• Capable of providing signed ICF and complying with the requirements and restrictions listed in the ICF and in this study protocol.

You may not qualify if…

• Prior treated with other MAT2A inhibitors and/or PRMT inhibitors.
• Participation in other therapeutic clinical studies within 28 days or 5 half-lives (whichever is shorter) prior to first dose of study treatment.
• Anti-tumor therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or other anti-tumor therapy, except for hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogues, agonists required to suppress serum testosterone levels) within 28 days or 5 half-lives, whichever is shorter prior to first dose of study treatment.
• Toxicities of prior therapy have not resolved to Grade ≤1 or to baseline (as evaluated by NCI CTCAE version 5.0)
• History of another primary tumor that has been diagnosed or required therapy within the past 3 years.
• Previous history of, or presence of Gilbert's syndrome.
• Previous history of myelodysplastic syndrome.
• Prior solid organ or hematopoietic stem cell transplant.
• Known active central nervous system (CNS) primary tumor or untreated CNS metastases.
• Have serious cardiovascular or cerebrovascular disease as per protocol.
• Presence of uncontrolled systemic infection as per protocol.
• Unwillingness or unable to comply with the requirements of oral drug administration, or presence of a gastro-intestinal condition.
• Other protocol inclusion and exclusion criteria may apply.

Where it is running

• Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States (enrolling)
• Smilow Cancer Hospital at Yale New Haven Breast Center — New Haven, Connecticut, United States (enrolling)
• Community Cancer Center North — Indianapolis, Indiana, United States (enrolling)
• SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China (enrolling)
• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)
• Sun Yat-sen university cancer center — Guangzhou, Guangdong, China (enrolling)
• Jiangsu Provincial People's Hospital — Nanjing, Jiangsu, China (enrolling)
• Shanghai Gobroad Cancer Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.